{
    "clinical_study": {
        "@rank": "149566", 
        "arm_group": [
            {
                "arm_group_label": "Group  I", 
                "arm_group_type": "Experimental", 
                "description": "Conventional analgesic treatment + pregabalin."
            }, 
            {
                "arm_group_label": "Group II", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Conventional analgesic treatment + placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double blind controlled, parallel arms trial, aimed to assess the\n      efficacy of pregabalin on pancreatic cancer induced abdominal pain. The goals of this study\n      include (1) assessing the analgesic effect of pregabalin in comparison to placebo; assessing\n      the presence of central sensitization and its potential reversion by Pregabalin; (3)\n      assessing quality of life of patients treated with pregabalin in comparison to placebo; (4)\n      to compare adverse effects in patients treated with Pregabalin in comparison to placebo; (5)\n      to compare anxiety and depression in patients treated with pregabalin in comparison to\n      placebo."
        }, 
        "brief_title": "Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer.", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Patients > 18 years old recently diagnosed of pancreatic cancer (<3 months).\n\n          -  2. Personally signed and dated informed consent document indicating that the patient\n             has been informed of all pertinent aspects of the trial.\n\n          -  3. Patients willing and able to comply with the scheduled visits, treatment plan,\n             laboratory tests and other trial procedures.\n\n        Exclusion Criteria:\n\n          -  1. Patients with evidence or history of medical or surgical disease of importance for\n             this study as judged by investigator.\n\n          -  2. Patients with previously diagnosed moderate to severe renal impairment. Those with\n             a Clearance of Creatinine (CLcr) < 60mL/min should be excluded.\n\n          -  3. Patients treated with anticonvulsants during the previous 4 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768988", 
            "org_study_id": "PANPAIN/1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group II", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group  I", 
                "description": "Treatment during 90 days with pregabalin.", 
                "intervention_name": "Pregabalin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pregabalin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2013", 
        "location": {
            "contact": {
                "email": "cdursteler@parcdesalutmar.cat", 
                "last_name": "D\u00fcrsteler Christian, PhD", 
                "phone": "0034 93 2483350"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08003"
                }, 
                "name": "Hospital del Mar"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study", 
        "overall_contact": {
            "email": "cdursteler@parcdesalutmar.cat", 
            "last_name": "D\u00fcrsteler Christian, PhD", 
            "phone": "0034 93 2483350"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analgesic effect of pregabalin therapy in pancreatic cancer patients, assessed using a visual analogue scale (VAS), the Brief Pain Inventory (BPI) and Neuropathic Pain Symptom Inventory (NPSI).", 
            "measure": "Pregabalin Therapy", 
            "safety_issue": "Yes", 
            "time_frame": "From baseline to day 90."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768988"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in quality of life compared to baseline level using SF-12 (Short-Form Health Survey) quality of life questionnaire.", 
                "measure": "Quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to day 90."
            }, 
            {
                "description": "Performance status (Karnofsky Performance Status Scale).", 
                "measure": "Performance status", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline until to day 90."
            }, 
            {
                "description": "Anxiety and depression will be also assessed, using Hospital Anxiety and Depression Scale (HADS).", 
                "measure": "Anxiety and depression", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to day 90."
            }
        ], 
        "source": "Parc de Salut Mar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Parc de Salut Mar", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}